Hyperphosphorylated tau protein (P-tau) in CSF is a core biomarker candidate of Alzheimer's
disease. Hyperphosphorylation of tau is thought to lead to neurofibrillary changes, a …

Background Imaging with amyloid-β PET can potentially aid the early and accurate
diagnosis of Alzheimer's disease. Florbetaben ( 18 F) is a promising 18 F-labelled amyloid-β-…

Background Abnormal hyperphosphorylation of the microtubule-associated protein tau and
its incorporation into neurofibrillary tangles are major hallmarks of the pathogenesis of …

Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical
Alzheimer's disease (AD). We asked to what extent the core biomarker candidates cerebro-spinal …

2-Deoxy-2-[ 18 F]fluoro-d-glucose positron emission tomography (FDG-PET) is widely used
to study cerebral glucose metabolism. Here, we investigated whether the FDG-PET signal is …

In this longitudinal study of 77 patients with mild cognitive impairment (MCI), the authors
analyzed whether levels of tau protein phosphorylated at threonine 231 (p-tau 231 ) in CSF …

Background Phosphorylation of tau protein at threonine 231 (using full-length tau, 441
amino acids, for the numbering scheme) (p-tau 231 ) occurs specifically in postmortem brain …

Functional MRI (fMRI) of default mode network (DMN) brain activity during resting state is
gaining attention as a potential non-invasive biomarker to diagnose incipient Alzheimer's …

Background Three small trials suggest that intravenous immunoglobulin can affect biomarkers
and symptoms of mild-to-moderate Alzheimer's disease. We tested the safety, effective …

We surveyed a total of 570 cerebrospinal fluid (CSF) samples from a variety of diseases,
including Alzheimer's disease (AD; n = 236), non‐AD‐demented and nondemented diseases (n …